Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. (Q37625446)

21 August 2017

1 reference

title

Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. (English)

1 reference

21 August 2017

hepatocellular carcinoma

1 reference

4

Koichi Tanaka

1 reference

21 August 2017

Donald Poon

1

1 reference

21 August 2017

Benjamin O Anderson

2

1 reference

21 August 2017

Li-Tzong Chen

3

1 reference

21 August 2017

Wan Yee Lau

5

1 reference

21 August 2017

Eric Van Cutsem

6

1 reference

21 August 2017

Harjit Singh

7

1 reference

21 August 2017

Wan Cheng Chow

8

1 reference

21 August 2017

London Lucien Ooi

9

1 reference

21 August 2017

Pierce Chow

10

1 reference

21 August 2017

Maung Win Khin

11

1 reference

21 August 2017

Wen Hsin Koo

12

1 reference

21 August 2017

Asian Oncology Summit

13

1 reference

21 August 2017

1 November 2009

1 reference

Lancet Oncology Commission

21 August 2017

1 reference

21 August 2017

10

1 reference

21 August 2017

11

1 reference

21 August 2017

1111-1118

1 reference

Detection of microcystins, a blue-green algal hepatotoxin, in drinking water sampled in Haimen and Fusui, endemic areas of primary liver cancer in China, by highly sensitive immunoassay

21 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Betel quid chewing as a risk factor for hepatocellular carcinoma: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Hepatitis B Virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: A Case‐Control study in Fukuoka, Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Epidemiology of hepatitis B virus infection in the Asia-Pacific region

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Epidemiology of hepatitis C virus in japan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Persistent hyperendemicity of hepatitis C virus infection in Taiwan: The important role of iatrogenic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Interactions between alcohol and hepatitis viruses in the liver.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Hepatitis C and alcohol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Global control of hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Causes of increased mortality from hepatocellular carcinoma in high incidence country: Taiwan experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Perinatal transmission of hepatitis B virus infection and vaccination in China

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Vertical Transmission of Hepatitis B Antigen in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

The e antigen and vertical transmission of hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Impact of hepatitis B immunisation as part of the EPI

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Changing corporate practices to reduce cancer disparities

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Randomized controlled trial of screening for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Extrahepatic Metastases of Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

One Thousand Fifty-Six Hepatectomies Without Mortality in 8 Years

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Assessment of hepatic reserve for indication of hepatic resection: how I do it

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Salvage surgery following downstaging of unresectable hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Yttrium-90 microspheres for the treatment of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970241-4

7 January 2021

Resection of Hepatocellular Carcinoma in Patients Otherwise Eligible for Transplantation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/S1470-2045(09)70241-4

Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/S1470-2045(09)70241-4

Identifiers

DOI

10.1016/S1470-2045(09)70241-4

1 reference

21 August 2017

1 reference